Biology subjects

Scorrano, L.

Publications and source records attributed to Scorrano, L..

5 recordsLinked to original sources

bioRxiv2026

Endothelial RRM2B-dependent mitochondrial DNA signalling drives doxorubicin-cardiotoxicity

Doxorubicin remains a mainstay of cancer therapy, yet its clinical use is constrained by severe cardiotoxicity, classically attributed to cardiomyocyte death. Here, we identify endothelial inflammation driven by mitochondrial DNA (mtDNA) turnover and release as a critical mediator of doxorubicin-induced cardiac injury. In vivo, a standard doxorubicin regimen activates the cGAS-STING innate immune pathway in endothelial cells before cardiomyocyte dysfunction or death occurs. Mechanistically, doxorubicin recruits the stress-inducible ribonucleotide reductase subunit RRM2B (p53R2) that normally sustains the mitochondrial deoxyribonucleotide pool, to promote aberrant mtDNA turnover and release, fuelling sterile inflammation. The FDA-approved BAX inhibitor Eltrombopag suppresses mtDNA release, attenuates endothelial inflammation, and prevents doxorubicin cardiotoxicity in vivo without compromising anticancer efficacy. These findings reveal an unrecognized proinflammatory role of RRM2B and establish endothelial inflammation as a central driver of chemotherapy-related cardiac injury, identifying the cardiac endothelium as a tractable target for cardioprotection during cancer treatment.

cell biology↗

bioRxiv2023

Activation of Ca2+ phosphatase Calcineurin regulates Parkin translocation to mitochondria and mitophagy

Selective removal of dysfunctional mitochondria via autophagy is crucial for the maintenance of cellular homeostasis. This event is initiated by the translocation of the E3 ubiquitin ligase Parkin to damaged mitochondria, and it requires the Serine/Threonine-protein kinase PINK1. In a coordinated set of events, PINK1 operates upstream of Parkin in a linear pathway that leads to the phosphorylation of Parkin, Ubiquitin, and Parkin mitochondrial substrates, to promote ubiquitination of outer mitochondrial membrane proteins. Ubiquitin decorated mitochondria are selectively recruiting autophagy receptors,which are required to terminate the organelle via autophagy. In this work we show a previously uncharacterized molecular pathway that correlates the activation of the Ca2+-dependent phosphatase Calcineurin to Parkin-dependent mitophagy. Calcineurin downregulation or genetic inhibition prevents Parkin translocation to CCCP-treated mitochondria, and impairs stress-induced mitophagy, whereas Calcineurin activation promotes Parkin mitochondrial recruitment and basal mitophagy. Calcineurin interacts with Parkin, and promotes Parkin translocation in the absence of PINK1, but requires PINK1 expression to execute mitophagy in MEF cells. Genetic activation of Calcineurin in vivo boosts basal mitophagy in neurons, and corrects locomotor dysfunction and mitochondrial respiratory defects of a Drosophila model of impaired mitochondrial functions. Our study identifies Calcineurin as a novel key player in the regulation of Parkin translocation and mitophagy.

cell biology↗

bioRxiv2020

Opa1 overexpression protects from early onset Mpv17-/--related mouse kidney disease

Moderate overexpression of Opa1, encoding a master regulator of mitochondrial cristae morphology, has been shown to improve significantly mitochondrial damage induced by drugs, surgical denervation, or genetically determined OXPHOS defects. However, this approach has been so far demonstrated in a limited number of genetically defective OXPHOS models characterized by specific impairment of a single mitochondrial respiratory chain complex. Here, we investigated the effectiveness of moderate Opa1 overexpression in the Mpv17-/- mouse, characterized by profound, multisystem mtDNA depletion. In naive Mpv17-/- individuals, whose genetic background was crossed with individuals belonging to the Opa1tg strain, we found a surprising anticipation of severe, progressive focal segmental glomerulosclerosis, previously described in Mpv17-/- animals as a late-onset clinical feature (after 12-18 months of life). In contrast, kidney failure led Mpv17-/- individuals from this new "mixed" strain leading to death 8-9 weeks after birth. However, Mpv17-/-::Opa1tg mice lived much longer than Mpv17-/- littermates, and developed much later severe proteinuria associated with focal segmental glomerulosclerosis. MtDNA content and OXPHOS activities were significantly higher in Mpv17-/-::Opa1tg than in Mpv17-/- kidneys, and similar to WT littermates. Mitochondrial network and cristae ultrastructure were largely preserved in Mpv17-/-::Opa1tg vs. Mpv17-/- kidney and isolated podocytes. Mechanistically, the protective effect of Opa1 overexpression in this model was mediated by a block in apoptosis due to the stabilization of the mitochondrial cristae, consequently increasing the levels of mitochondrial morphology proteins like MFN2 and MIC19 as well as stabilizing ATP synthase oligomers. These results demonstrate that strategies aiming at increasing Opa1 expression or activity can be an effective aid against mtDNA depletion syndromes.

pathology↗

bioRxiv2018

Lipid utilization in skeletal muscle cells is modulated in vitro and in vivo by specific miRNAs

Skeletal muscle is composed by different myofiber types that can preferentially use glycolysis or lipids for ATP production. How fuel preference is specified in these post-mitotic cells is unknown. Here we show that miRNAs are important players in defining the myofiber metabolic profile. mRNA and miRNA signatures of all myofiber types obtained at single cell level unveiled fiber-specific regulatory networks and identified two master miRNAs that coordinately control myofiber fuel preference and mitochondrial morphology. Our work provides a complete and integrated myofiber type-specific catalogue of genes and miRNAs expressed and establishes miR-27a-3p and miR-142-3p as key regulators of lipid utilization in skeletal muscle.\n\nHIGHLIGHTSO_LITranscriptional networking in single cells distinguished myofibers based on glycolytic or oxidative metabolism, regulated by specific miRNAs\nC_LIO_LImiR-27a-3p and -142-3p influence mitochondrial morphology\nC_LIO_LImiR-27a-3p improves lipid utilization and increases glycogen storage both in vitro and in vivo\nC_LIO_LImiR-142-3p reduces lipid utilization both in vitro and in vivo\nC_LI

genomics↗

bioRxiv2017

Mutational signatures reveal the role of RAD52 in p53-independent p21 driven genomic instability

BackgroundGenomic instability promotes evolution and heterogeneity of tumors. Unraveling its mechanistic basis is essential to design appropriate therapeutic strategies. In a recent study we reported an unexpected oncogenic property of p21WAF1/Cip1 showing that its chronic expression, in a p53-deficient environment, causes genomic instability by deregulating the replication licensing machinery.\n\nResultsExtending on this work we now demonstrate that p21WAF1/Cip1 can further fuel genomic instability by suppressing the repair capacity of low and high fidelity pathways that deal with nucleotide abnormalities. Consequently, fewer single nucleotide substitutions (SNSs) occur, while formation of highly deleterious DNA double-strand breaks (DSBs) is enhanced, crafting a characteristic mutational signature landscape. Guided by the mutational signatures formed, we found at the mechanistic level that the DSBs were repaired by Rad52-dependent Break-Induced Replication (BIR) and Single-Strand Annealing (SSA). Conversely, the error-free synthesis-dependent strand annealing (SDSA) repair route was deficient. Surprisingly, Rad52 was activated transcriptionally in an E2F1-dependent manner, rather than post-translationally as is common for DNA repair factor activation.\n\nConclusionsOur results signify the importance of mutational signatures as guides to disclose the \"repair history\" leading to genomic instability. In this vein, following this approach we unveiled how chronic p21WAF1/Cip1 expression rewires the repair process, identifying Rad52 as a source of genomic instability and a candidate therapeutic target.

cancer biology↗